| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00125-009-1619-X |
| P8608 | Fatcat ID | release_ajwznrtjv5fpzj5wvukonnpowy |
| P698 | PubMed publication ID | 19957160 |
| P5875 | ResearchGate publication ID | 40444242 |
| P50 | author | Kevin J Woollard | Q31229594 |
| Anna Watson | Q42615922 | ||
| Terri J. Allen | Q46601755 | ||
| P2093 | author name string | Z Cao | |
| M E Cooper | |||
| T Walther | |||
| L Loufrani | |||
| A Soro-Paavonen | |||
| A Koïtka | |||
| K A M Jandeleit-Dahm | |||
| K C Sourris | |||
| P Koh | |||
| P2860 | cites work | Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice | Q24303396 |
| International union of pharmacology. XXIII. The angiotensin II receptors | Q28138041 | ||
| Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators | Q28144781 | ||
| Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture | Q28173922 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 | ||
| Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia | Q72019101 | ||
| A noninvasive computerized tail-cuff system for measuring blood pressure in mice | Q72210808 | ||
| Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy | Q72997555 | ||
| "The road not taken": role of angiotensin II type 2 receptor in pathophysiology | Q77550177 | ||
| Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice | Q77862249 | ||
| Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor | Q28283897 | ||
| Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis | Q28362086 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function | Q30304616 | ||
| Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney | Q30471269 | ||
| Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats | Q30481218 | ||
| Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization | Q31956534 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system | Q34287883 | ||
| The AT2 receptor--a matter of love and hate | Q34436809 | ||
| Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases | Q36310340 | ||
| Recipes for creating animal models of diabetic cardiovascular disease | Q36831539 | ||
| Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes | Q36842628 | ||
| Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors | Q36918543 | ||
| Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. | Q37357707 | ||
| Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections | Q39572948 | ||
| The angiotensin AT2 receptor: searching for signal-transduction pathways and physiological function. | Q40478363 | ||
| Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts | Q41009444 | ||
| Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. | Q43511818 | ||
| Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury | Q44044855 | ||
| Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice | Q44053753 | ||
| RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. | Q44228474 | ||
| Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. | Q44581607 | ||
| Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis | Q44801373 | ||
| Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. | Q44903329 | ||
| Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. | Q44953934 | ||
| Angiotensin II, type 2 receptor is not involved in the angiotensin II-mediated pro-atherogenic process in ApoE-/- mice. | Q46589150 | ||
| Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects | Q46601696 | ||
| Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice | Q46689553 | ||
| Renal angiotensin II AT2 receptors promote natriuresis in streptozotocin-induced diabetic rats | Q46735589 | ||
| Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution | Q46802781 | ||
| Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects | Q46847408 | ||
| Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? | Q54506199 | ||
| Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system | Q57583262 | ||
| Angiotensin type 2 receptor is expressed in human atherosclerotic lesions | Q62089642 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| P433 | issue | 3 | |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 584-592 | |
| P577 | publication date | 2009-12-03 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes | |
| P478 | volume | 53 |
| Q38167346 | Angiotensin II receptor antagonists in acute coronary syndromes |
| Q36123417 | Association between renin and atherosclerotic burden in subjects with and without type 2 diabetes. |
| Q36025434 | Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. |
| Q54397160 | Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. |
| Q46506399 | Effects of angiotensin II type 1 receptor blocker on bones in mice with type 1 diabetes induced by streptozotocin. |
| Q45859011 | Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes. |
| Q33803026 | Genetic variants of the Renin Angiotensin system: effects on atherosclerosis in experimental models and humans |
| Q90632374 | Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease |
| Q37921158 | LOX-1 and angiotensin receptors, and their interplay |
| Q38125279 | Molecular biology of atherosclerosis |
| Q37990618 | Novel pathways and therapies in experimental diabetic atherosclerosis |
| Q41971058 | Opposite effects of angiotensins receptors type 2 and type 4 on streptozotocin induced diabetes vascular alterations in mice |
| Q31115399 | PD123319 augments angiotensin II-induced abdominal aortic aneurysms through an AT2 receptor-independent mechanism |
| Q53814713 | Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice. |
| Q38771740 | The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis. |
| Q38200957 | The pathobiology of diabetic vascular complications--cardiovascular and kidney disease |
Search more.